RED- Treatment of vulvar and vaginal atrophy in postmenopausal women having
moderate to severe symptoms. Second line to vaginal oestrogen in women who
have not had symptom improvement with standard doses of vaginal oestrogen. Agreed based on lower level evidence against placebo.
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
5: Is new to clinical practice and unfamiliar, necessitating a period of accumulation of experience, firstly (and most rapidly) by consultants/specialists
